<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1192">
  <stage>Registered</stage>
  <submitdate>5/04/2006</submitdate>
  <approvaldate>11/04/2006</approvaldate>
  <actrnumber>ACTRN12606000132549</actrnumber>
  <trial_identification>
    <studytitle>Randomised crossover trial of a porous haemodialysis membrane compared to a conventional high-flux membrane in stable haemodialysis patients to determine the short term impact on inflammatory and nutritional indices.</studytitle>
    <scientifictitle>Randomised crossover trial of a porous haemodialysis membrane compared to a conventional high-flux membrane in stable haemodialysis patients to determine the short term impact on inflammatory and nutritional indices.</scientifictitle>
    <utrn />
    <trialacronym>Nil</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Haemodialysis</healthcondition>
    <healthcondition>End Stage Renal Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>30 stable haemodialysis patients will be randomly assigned to either continue on conventional high-flux dialysis with the FX60 membrane or the new modified-FX membrane.  Equal numbers in each group.  Cross-over after 6 weeks.  Total study duration 12 weeks.</interventions>
    <comparator>Conventional high-flux dialysis with the FX60 membrane </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Nutritional indices</outcome>
      <timepoint>Assessed in the serum at baseline, 2,6, 8 and 12 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Inflammatory indices</outcome>
      <timepoint>Assessed in the serum at baseline, 2,6, 8 and 12 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Dialysate albumin</outcome>
      <timepoint>Assessed in the serum at baseline, 2,6, 8 and 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum albumin, URR (urea reduction ratio).</outcome>
      <timepoint>Assessed at baseline and at 6 and 12 weeks.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Stable haemodialysis patients, currently dialysed with FX60 dialysers. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by third party using random number chart generated by computer package</concealment>
    <sequence>random number generation by computer</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>30/06/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Fresenius</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Germany</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Fresenius Asia-Pacific</fundingname>
      <fundingaddress>Hong Kong</fundingaddress>
      <fundingcountry>Hong Kong</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial examines whether a new dialysis membrane has potential advantages to the patients by way of determining whether the membrane results in less of an inflammatory state - reflected by both markers of inflammation and nutrition in the blood.  It is a short term pilot study only, as a possible lead in to a longer more detailed study.  The dialysis membranes will be supplied blinded in that all will look the same (but carry a code) such that the treating dialysis nurses and the patients will be unaware of which dialyser is in use at any given time.</summary>
    <trialwebsite />
    <publication>Accepted in Am J Kidney Dis - yet to be published</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Kerr</name>
      <address>Nephrology
Monash Medical Centre
246 Clayton Rd
Clayton VIC 3168</address>
      <phone>+61 3 95943520</phone>
      <fax>+61 3 95946530</fax>
      <email>peter.kerr@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Peter Kerr</name>
      <address>Nephrology
Monash Medical Centre
246 Clayton Rd
Clayton VIC 3168</address>
      <phone>+61 3 95943520</phone>
      <fax>+61 3 95946530</fax>
      <email>peter.kerr@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>